Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies
Applied StemCell and the California Institute for Regenerative Medicine (CIRM) have partnered as Industry Resource […]
HuidaGene Therapeutics' Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO
HuidaGene Therapeutics, a clinical-stage company focusing on developing gene editing tools and gene therapies, today […]
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research for DMD
Precision BioSciences, a clinical-stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and […]
Synthego Launches Express Cell Pools for Faster, More Efficient Genome Editing
Synthego, a leading provider of genome engineering solutions, has announced the launch of Express Knockout […]
Vertex and CRISPR Therapeutics Announce Licensing Agreement
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that they have entered into a new non-exclusive […]
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform
Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further […]
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology
Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion […]
New AI Tool Makes Speedy Gene Editing Possible
An artificial intelligence (AI) program may enable the first simple production of customizable proteins called […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more